Orsolya Módos

646 total citations
15 papers, 347 citations indexed

About

Orsolya Módos is a scholar working on Surgery, Urology and Oncology. According to data from OpenAlex, Orsolya Módos has authored 15 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 5 papers in Urology and 4 papers in Oncology. Recurrent topics in Orsolya Módos's work include Urinary and Genital Oncology Studies (12 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urological Disorders and Treatments (5 papers). Orsolya Módos is often cited by papers focused on Urinary and Genital Oncology Studies (12 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urological Disorders and Treatments (5 papers). Orsolya Módos collaborates with scholars based in Hungary, Germany and Austria. Orsolya Módos's co-authors include Tibor Szarvas, Péter Nyírády, Henning Reis, Christian Niedworok, Attila Szendrői, Marcell A. Szász, Boris Hadaschik, Ulrich Krafft, András Horváth and H. Rübben and has published in prestigious journals such as Scientific Reports, The Journal of Urology and Oncotarget.

In The Last Decade

Orsolya Módos

15 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Orsolya Módos Hungary	9	260	174	64	58	50	15	347
Christoph Kakies Germany	8	174 0.7×	67 0.4×	109 1.7×	46 0.8×	55 1.1×	11	320
Vanessa Henriques Portugal	8	197 0.8×	37 0.2×	104 1.6×	106 1.8×	110 2.2×	18	374
Taizo Uchimoto Japan	11	104 0.4×	74 0.4×	100 1.6×	89 1.5×	58 1.2×	21	281
Jordan Kardos United States	7	129 0.5×	31 0.2×	111 1.7×	78 1.3×	80 1.6×	11	254
Zhi-Ling Zhang China	11	146 0.6×	46 0.3×	125 2.0×	99 1.7×	77 1.5×	22	331
Gudrun Schlake Germany	4	207 0.8×	45 0.3×	106 1.7×	51 0.9×	56 1.1×	9	284
Shengliang Shi China	3	244 0.9×	22 0.1×	185 2.9×	70 1.2×	140 2.8×	6	346
Aleksander Ślusarczyk Poland	9	111 0.4×	34 0.2×	37 0.6×	36 0.6×	85 1.7×	33	210
Michael Wittlinger Germany	8	178 0.7×	69 0.4×	77 1.2×	66 1.1×	152 3.0×	14	381
David Morris United States	8	65 0.3×	23 0.1×	64 1.0×	102 1.8×	68 1.4×	25	224

Countries citing papers authored by Orsolya Módos

Since Specialization

Citations

This map shows the geographic impact of Orsolya Módos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Orsolya Módos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Orsolya Módos more than expected).

Fields of papers citing papers by Orsolya Módos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Orsolya Módos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Orsolya Módos. The network helps show where Orsolya Módos may publish in the future.

Co-authorship network of co-authors of Orsolya Módos

This figure shows the co-authorship network connecting the top 25 collaborators of Orsolya Módos. A scholar is included among the top collaborators of Orsolya Módos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Orsolya Módos. Orsolya Módos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Módos, Orsolya, Tamás Fazekas, Günter Niegisch, et al.. (2023). Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study. Scientific Reports. 13(1). 17378–17378. 4 indexed citations

Krafft, Ulrich, Csilla Oláh, Henning Reis, et al.. (2021). High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers. 13(11). 2548–2548. 24 indexed citations

Oláh, Csilla, Stephan Tschirdewahn, Michèle J. Hoffmann, et al.. (2020). Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics. 10(11). 864–864. 8 indexed citations

Módos, Orsolya, et al.. (2020). A húgyhólyag-recidíva jellemzői felső üregrendszeri daganatos betegekben radikális ureteronephrectomia után. Orvosi Hetilap. 161(21). 881–888. 1 indexed citations

Krafft, Ulrich, Stephan Tschirdewahn, Nina N. Harke, et al.. (2019). STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. Pathology & Oncology Research. 26(2). 1243–1249. 12 indexed citations

Krafft, Ulrich, Stephan Tschirdewahn, Jochen Heß, et al.. (2019). Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urologic Oncology Seminars and Original Investigations. 37(11). 810.e7–810.e15. 27 indexed citations

Módos, Orsolya, Miklós Szűcs, Thilo Bracht, et al.. (2019). Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer. European Urology Supplements. 18(1). e482–e482. 1 indexed citations

Szarvas, Tibor, Sabina Sevcenco, Orsolya Módos, et al.. (2018). Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 36(6). 312.e9–312.e15. 22 indexed citations

Szarvas, Tibor, Sabina Sevcenco, Orsolya Módos, et al.. (2018). Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration‐resistant prostate cancer. British Journal of Urology. 122(4). 695–704. 7 indexed citations

10.

Reis, Henning, Ulrich Krafft, Christian Niedworok, et al.. (2018). Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Disease Markers. 2018. 1–21. 39 indexed citations

11.

Szarvas, Tibor, Orsolya Módos, Christian Niedworok, et al.. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 cases. Urologic Oncology Seminars and Original Investigations. 34(9). 388–398. 117 indexed citations

12.

Szarvas, Tibor, Orsolya Módos, András Horváth, & Péter Nyírády. (2016). Why are upper tract urothelial carcinoma two different diseases?. Translational Andrology and Urology. 5(5). 636–647. 19 indexed citations

13.

Módos, Orsolya, Henning Reis, Christian Niedworok, et al.. (2016). Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget. 7(26). 39293–39301. 35 indexed citations

14.

Módos, Orsolya, Tibor Szarvas, Henning Reis, et al.. (2015). Mutation analysis of EGFR signal transduction pathway in urachal carcinoma. European Urology Supplements. 14(6). e1215–e1215. 3 indexed citations

15.

Niedworok, Christian, Tibor Szarvas, Henning Reis, et al.. (2015). Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. The Journal of Urology. 195(6). 1690–1696. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact